The wound healing market is  worth approximately 20 bn USD in 2020. The global wound care market is expected to hit 25 bn USD by 2027 (Fortune Business Insight 2020).

The US market is dominating, but largest growth is in Asia-Pacific

  

  

  

  

  

Overview  -  "Strongest growth in the advanced wound market"

(back to index)

The wound healing market is roughly is split into 3 segments, "Basic", "Surgical" and "Advanced" of roughly the same size re value (Figure 1)

Regenics adresses all market segments.

3 bioactive products are in development; Vernex® (spray), Collex® (3D printed patch) and WoundClear® (debridement enzyme). Vernex® and Collex® are Medical Devices, WoundClear, a novel debridement enzyme, is a drug.

Vernex®  and WounClear® is delivered in a practical  BoV (bag on valve) spray/foam containing salmon roe extract. Collex®  is an all marine 3D printed wound patch for the "bioengineered skin" segment. WoundClear® is agenetically engineered novel marine enzyme for enzymatic wound debridement

The "Advanced" cathegory in total shows jointly a very strong (< 14% ) annual growth and see a value of 5 bn USD in 2020. The "Basic" cathegory of wound care products (simple gauze, cover and protect devices is stable or in slight decline. 

Figure 1

  

The global wound care market is expected to reach USD 20.4 Billion by 2021  having experienced a growth rate at a CAGR of 3.6% from 2016 to 2021.

The factors driving the market growth include rising aging population, government support in the form of funding for development of wound care products, increasing incidence of chronic diseases such as diabetes and growing obese population. However, factors such as high costs of advanced wound care products may restrain the market growth; especially in the cost-sensitive market.

Key Companies  -  "A few companies have 55% of the market"

(back to index)

Figure 2

 Four major companies, including Smith & Nephew. Kinetic Concepts, Molnlycke, and ConvaTec comprise more than 55% of the approx. $5 billion "Advanced" cathegory wound care market in 2020.

Regenics strategy is both to bring 2 products to the market and to license the technology to a major player, making sure that the product development will create appropriate asset value, but also to keep a certain part of the products or line extensions for selected markets.

The bioactive market, is of particular focus for Regenics for potential licencing. This subset market is also dominated by a few large players:

 

Ohter significant players that is particularly active in the Advanced Wound care market are:

  • Acelity
  • Advanced Medical Solutions
  • Aso
  • Aspen Surgical Products
  • Avita Medical
  • Bastos Viegas
  • BioDlogics
  • BSN Medical
  • Capilano
  • Cardinal Health
  • ConvaTec
  • Cytori Therapeutics
  • Derma Sciences
  • DeRoyal Industries
  • GELITA
  • Hartmann
  • HemCon Medical Technologies
  • Intercytex
  • Johnson and Johnson
  • Kinetic Concepts
  • Kuros Biosurgery
  • Lohmann & Rauscher
  • MacroCure
  • Medline Industries
  • Medtronic (Covidien)
  • Meyer-Haake Medical Innovations
  • Nuo Therapeutics
  • Organogenesis
  • Osiris Therapeutics
  • ProFibrix
  • Regenerys
  • Sutherland Medical
  • Tepha

 

Advanced segment  -  "Growth factors" and "Artificial skin" grow > 14% "

(back to index)

Figure 3

 

The "Advanced Segment" of wound care involves a heterogeneous group of products as shown in Figure 3. The "Advanced Segment" of wound care are also presented together with the advanced parts of Surgical Segment. Combined these two segment is expected to grow to around 20 bn USD by end 2020 (Markets and Markets). 

Regenics thus adresses a  global market of 2 bn USD as of 2020 for the relevant 2 product cathegories of the wound healing market (Figure 4), which is expected to represent a 10-12% market share.

Bioengineered Skin   -  "Collagen and 3D - bioprinting" 

(back to index)

Figure 5

Bioengineered skin are bioengineered skin substitutes either from collagen matrices, other synthtic matrices or 3D bioprinting. 

Growth Factors   -  "Complex, but significant growth" 

(back to index)

Figure 6

 

The "Growth Factor" segment covers a multitude of agents that affect the complex chain of biogical events and cells that contribute to skin regeneration after injury. Most products combines physical, protective elements with biotargeting of effector cells or bioprocesses. The growth factors or bioeffectiors are often administered in topical carrier formulation that supports or potentiated the effects. 

Technavio's analysts forecast the global bioactive wound care market to grow at a CAGR of 13.85% during the period 2016-2020.

Treatment with growth factors is an effective method to promote wound healing. Several growth factors have been used in wound treatment, including basic fibroblast growth factor (bFGF) discovered in the 1970s, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and bone morphogenetic protein (BMP).

 

 

 

Regenics AS adresses the advanced wound care market with Vernex® (spray) and Collex® (3D printed patch ) ...........The global advanced wound care market is expected to reach USD 16.5 billion by 2025 from USD 10.3 billion in 2020, at a CAGR of 9.8%. Market growth is expected to grow due to factors like the rapidly growing geriatric population, rising incidence of diabetes, technological advancements in wound care products, funding for wound care research, and growing awareness of wound management. (Marketsandmarkets 2020)

Regenics AS adresses the enzymatic wound debridemen market with WoundClear® enzymatic foam.... The wound debridement market is projected to reach a value of USD 1,162 million by 2025 from USD 822 million in 2020, at a CAGR of 7.2% from 2020 to 2025.                              (Marketsandmarkets 2020)

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.